WO2005014046A3 - Compositions for delivery of therapeutics into the eyes and methods for making and using the same - Google Patents

Compositions for delivery of therapeutics into the eyes and methods for making and using the same Download PDF

Info

Publication number
WO2005014046A3
WO2005014046A3 PCT/US2004/025540 US2004025540W WO2005014046A3 WO 2005014046 A3 WO2005014046 A3 WO 2005014046A3 US 2004025540 W US2004025540 W US 2004025540W WO 2005014046 A3 WO2005014046 A3 WO 2005014046A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
therapeutics
eyes
delivery
making
Prior art date
Application number
PCT/US2004/025540
Other languages
French (fr)
Other versions
WO2005014046A2 (en
Inventor
Joseph G Vehige
James N Chang
Richard Graham
Robert T Lyons
Teresa H Kuan
Chin-Ming Chang
Original Assignee
Allergan Inc
Joseph G Vehige
James N Chang
Richard Graham
Robert T Lyons
Teresa H Kuan
Chin-Ming Chang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34138742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005014046(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK04780382.0T priority Critical patent/DK1654002T4/en
Priority to AU2004263149A priority patent/AU2004263149B2/en
Priority to DE602004023516T priority patent/DE602004023516D1/en
Priority to JP2006522767A priority patent/JP2007501799A/en
Priority to ES04780382.0T priority patent/ES2332049T5/en
Application filed by Allergan Inc, Joseph G Vehige, James N Chang, Richard Graham, Robert T Lyons, Teresa H Kuan, Chin-Ming Chang filed Critical Allergan Inc
Priority to AT04780382T priority patent/ATE444732T1/en
Priority to BRPI0413381-1A priority patent/BRPI0413381A/en
Priority to PL04780382T priority patent/PL1654002T5/en
Priority to CA002534484A priority patent/CA2534484A1/en
Priority to EP04780382.0A priority patent/EP1654002B2/en
Publication of WO2005014046A2 publication Critical patent/WO2005014046A2/en
Publication of WO2005014046A3 publication Critical patent/WO2005014046A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco­adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.
PCT/US2004/025540 2003-08-07 2004-08-05 Compositions for delivery of therapeutics into the eyes and methods for making and using the same WO2005014046A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP04780382.0A EP1654002B2 (en) 2003-08-07 2004-08-05 Compositions for delivery of therapeutics into the eyes
AU2004263149A AU2004263149B2 (en) 2003-08-07 2004-08-05 Compositions for delivery of therapeutics into the eyes and methods for making and using same
DE602004023516T DE602004023516D1 (en) 2003-08-07 2004-08-05 COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS TO EYES AND METHOD FOR THEIR PRODUCTION AND USE
JP2006522767A JP2007501799A (en) 2003-08-07 2004-08-05 Composition for delivering a medicament into the eye and methods for its preparation and use
ES04780382.0T ES2332049T5 (en) 2003-08-07 2004-08-05 Compositions of administration of therapeutic substances in the eyes
DK04780382.0T DK1654002T4 (en) 2003-08-07 2004-08-05 Compositions for applying therapeutic agents to the eyes
AT04780382T ATE444732T1 (en) 2003-08-07 2004-08-05 COMPOSITIONS FOR DELIVERING THERAPEUTICS INTO THE EYES AND METHODS FOR THE PRODUCTION AND USE THEREOF
BRPI0413381-1A BRPI0413381A (en) 2003-08-07 2004-08-05 compositions for releasing therapeutic compounds into the eyes and processes for the manufacture and use thereof
PL04780382T PL1654002T5 (en) 2003-08-07 2004-08-05 Compositions for delivery of therapeutics into the eyes
CA002534484A CA2534484A1 (en) 2003-08-07 2004-08-05 Compositions for delivery of therapeutics into the eyes and methods for making and using same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49317803P 2003-08-07 2003-08-07
US49318803P 2003-08-07 2003-08-07
US60/493,188 2003-08-07
US60/493,178 2003-08-07

Publications (2)

Publication Number Publication Date
WO2005014046A2 WO2005014046A2 (en) 2005-02-17
WO2005014046A3 true WO2005014046A3 (en) 2006-06-01

Family

ID=34138742

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025540 WO2005014046A2 (en) 2003-08-07 2004-08-05 Compositions for delivery of therapeutics into the eyes and methods for making and using the same

Country Status (12)

Country Link
US (4) US8512717B2 (en)
EP (2) EP1654002B2 (en)
JP (1) JP2007501799A (en)
AT (1) ATE444732T1 (en)
AU (1) AU2004263149B2 (en)
BR (1) BRPI0413381A (en)
CA (1) CA2534484A1 (en)
DE (1) DE602004023516D1 (en)
DK (1) DK1654002T4 (en)
ES (2) ES2332049T5 (en)
PL (1) PL1654002T5 (en)
WO (1) WO2005014046A2 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052516A2 (en) 1999-03-01 2000-09-08 Boston Innovative Optics, Inc. System and method for increasing the depth of focus of the human eye
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US7628810B2 (en) * 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
US20050046794A1 (en) * 2003-06-17 2005-03-03 Silvestrini Thomas A. Method and apparatus for aligning a mask with the visual axis of an eye
WO2005014046A2 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
CN1993118B (en) * 2004-11-05 2010-06-16 千寿制药株式会社 Aqueous eye drops with accelerated intraocular migration permeability
US7976577B2 (en) 2005-04-14 2011-07-12 Acufocus, Inc. Corneal optic formed of degradation resistant polymer
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US7976833B2 (en) * 2005-10-14 2011-07-12 Aspen Biomedical Research, Llc Ophthalmic surgical irrigating solutions containing hyaluronidase and method for preventing post-operative intraocular pressure increases
EP1978926A2 (en) * 2005-12-19 2008-10-15 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses thereof
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
MX2010003364A (en) 2007-10-08 2010-07-06 Lux Biosciences Inc Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors.
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
AU2010259184B2 (en) * 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US9492272B2 (en) 2009-08-13 2016-11-15 Acufocus, Inc. Masked intraocular implants and lenses
USD656526S1 (en) 2009-11-10 2012-03-27 Acufocus, Inc. Ocular mask
US8921337B2 (en) 2009-12-03 2014-12-30 Alcon Research, Ltd. Carboxyvinyl polymer-containing nanoparticle suspensions
RU2452478C1 (en) * 2011-02-21 2012-06-10 Общество с ограниченной ответственностью "Научно-производственная компания Уралбиофарм" Multipurpose solution for epibulbar instillations
SG11201402305WA (en) 2011-11-21 2014-06-27 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
US9545303B2 (en) 2011-12-02 2017-01-17 Acufocus, Inc. Ocular mask having selective spectral transmission
EP2690604B1 (en) 2012-07-24 2021-05-26 Scan Coin Ab Coin deposit and dispensing apparatus
EP2690607B1 (en) 2012-07-24 2024-03-27 Scan Coin Ab Apparatus, method and computer program for flexible dispensing of coins in a coin handling apparatus
EP2690605B1 (en) 2012-07-24 2015-04-29 Scan Coin Ab Dispensers for coin handling apparatus
RU2644257C2 (en) 2012-07-26 2018-02-08 Аллерган, Инк. Packaging / capping system with two covers to maintain the sterility of the dosing tip during storage
MX2015005963A (en) 2012-11-16 2015-09-16 Calithera Biosciences Inc Heterocyclic glutaminase inhibitors.
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
BR112016014404A2 (en) * 2013-12-18 2017-08-08 Gnt Llc COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA
JP6798890B2 (en) 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ， インコーポレイテッド Combination therapy with glutaminase inhibitors
BR112017002403A2 (en) 2014-08-07 2017-12-05 Calithera Biosciences Inc crystal forms of glutaminase inhibitors
UY36272A (en) 2014-08-13 2016-02-29 Eolas Therapeutics Inc DIFLUOROPIRROLIDINS AS MODULATORS OF OREXIN RECEPTORS
AU2016230793B2 (en) 2015-03-10 2021-03-25 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
CA2990192A1 (en) 2015-06-23 2016-12-29 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
JP6971239B2 (en) 2015-10-05 2021-11-24 キャリセラ バイオサイエンシーズ， インコーポレイテッド Combination therapy with glutaminase inhibitor and immunooncology drug
EP4011887A1 (en) 2015-10-30 2022-06-15 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
BR112018009946A8 (en) 2015-11-16 2019-02-26 Ichorion Therapeutics Inc nucleic acid prodrugs
EP3414241B1 (en) 2016-02-12 2022-05-04 Astrazeneca AB Halo-substituted piperidines as orexin receptor modulators
US10793590B2 (en) 2016-06-03 2020-10-06 President And Fellows Of Harvard College Antifungal compounds
KR102275012B1 (en) 2016-08-12 2021-07-07 실크 테크놀로지스 리미티드 Silk-derived protein for the treatment of inflammation
AU2017311636B2 (en) * 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
CN110234656B (en) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 Exonucleotidase inhibitors and methods of use thereof
EP3509583B1 (en) 2016-09-09 2021-06-30 The Regents of the University of California Estrogen receptor ligands, compositions and methods related thereto
EP3512834A4 (en) 2016-09-14 2020-05-06 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
JP7203018B2 (en) 2016-09-26 2023-01-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Chromobox protein inhibitors and uses thereof
KR20190104521A (en) 2016-11-08 2019-09-10 칼리테라 바이오사이언시즈, 인코포레이티드 Arginase Inhibitor Combination Therapies
AU2017382405B2 (en) 2016-12-22 2021-12-16 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
JP2020511424A (en) 2017-01-18 2020-04-16 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ Fused heterocyclic compounds as selective BMP inhibition
EP3585772B1 (en) 2017-02-24 2023-10-11 Merck Patent GmbH 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
US11325943B2 (en) 2017-06-02 2022-05-10 Stealth Biotherapeutics Inc. Crystalline salt forms of SBT-20
EP3655379B1 (en) 2017-07-19 2023-04-05 California Institute of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds
SG11202003081WA (en) 2017-10-11 2020-05-28 Aurigene Discovery Tech Ltd Crystalline forms of 3-substituted 1,2,4-oxadiazole
WO2019087087A1 (en) 2017-11-03 2019-05-09 Aurigene Discovery Technologies Limited Dual inhibitors of tim-3 and pd-1 pathways
CN111386128A (en) 2017-11-06 2020-07-07 奥瑞基尼探索技术有限公司 Combination therapy for immunomodulation
UY38027A (en) 2017-12-22 2019-07-31 Medimmune Ltd KEAP1 BTB DOMAIN SMALL MOLECULE MODULATORS
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
SG11202100429TA (en) 2018-07-27 2021-02-25 California Inst Of Techn Cdk inhibitors and uses thereof
CA3111217A1 (en) 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
CA3117695A1 (en) 2018-10-26 2020-04-30 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
CN113727736A (en) 2018-12-10 2021-11-30 通用医疗公司 Cromoglycate and its use
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
JP2022525157A (en) 2019-03-14 2022-05-11 アストラゼネカ・アクチエボラーグ Lana Becestat for Weight Loss
JP6890865B1 (en) 2019-06-03 2021-06-18 株式会社大分大学先端医学研究所 Cyclic amide compounds for the treatment of rabies and methods thereof
CA3157798A1 (en) 2019-11-12 2021-05-20 Zhongli Gao 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
US20230088747A1 (en) 2019-12-16 2023-03-23 Unist (Ulsan National Institute Of Science And Technology) Compounds for inhibiting neovascularization factors and use thereof
TW202309022A (en) 2021-04-13 2023-03-01 美商努法倫特公司 Amino-substituted heterocycles for treating cancers with egfr mutations
WO2023034992A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
TW202320768A (en) 2021-10-01 2023-06-01 美商努法倫特公司 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023056431A1 (en) 2021-10-01 2023-04-06 Nuvalent, Inc. Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
TW202400608A (en) 2022-04-07 2024-01-01 美商努法倫特公司 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023196910A1 (en) 2022-04-07 2023-10-12 Nuvalent, Inc Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2024036098A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2007091A (en) * 1977-11-07 1979-05-16 Toko Yakuhin Kogyo Kk Ophthalmic composition
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
WO1992002515A1 (en) * 1990-07-31 1992-02-20 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6056950A (en) * 1996-02-05 2000-05-02 Farmigea S.P.A. Ophthalmic solutions viscosified with tamarind seed polysaccharide
US6255299B1 (en) * 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
US20020103255A1 (en) * 1997-12-19 2002-08-01 Hellberg Mark R. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1781701A (en) 1928-05-16 1930-11-18 Phillips Morris Godfrey Philip Machine for removing flags and other adhering leaf from the stalks of tobacco leaves
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
BE795970A (en) 1972-02-29 1973-08-27 Pfizer NEW DERIVATIVES OF QUINOLEINE, QUINOXALINE AND QUINAZOLINE ER PHARMACEUTICAL COMPOSITION CONTAINING THEM
US4089969A (en) 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US4474787A (en) 1977-05-04 1984-10-02 Fisons Limited 7,6 Dioxo-4H,6H-pyrano[3,2-g]quinoline dicarboxylic acids and anti-allergic use thereof
GB2013084B (en) * 1978-01-25 1982-07-28 Alcon Lab Inc Ophthalmic drug dosage
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
GB8500310D0 (en) * 1985-01-07 1985-02-13 Leo Pharm Prod Ltd Pharmaceutical preparation
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
CA1328614C (en) 1987-09-11 1994-04-19 Cherng-Chyi Roger Fu Preservative system for ophthalmics formulations
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US6174999B1 (en) * 1987-09-18 2001-01-16 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5705485A (en) * 1987-09-18 1998-01-06 Ethicon, Inc. Gel formulations containing growth factors
US5527893A (en) * 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5017229A (en) 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US4861514A (en) 1988-06-08 1989-08-29 The Drackett Company Compositions containing chlorine dioxide and their preparation
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5721275A (en) 1989-06-07 1998-02-24 Bazzano; Gail S. Slow release vehicles for minimizing skin irritancy of topical compositions
US5045121A (en) 1989-06-21 1991-09-03 Gte Products Corporation Method for removing carbon from cemented tungsten carbide articles
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
IT1250691B (en) 1991-07-22 1995-04-21 Giancarlo Santus THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC.
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
DE69304071T2 (en) * 1992-07-06 1996-12-19 Hansen Transmissions Int GEARBOX
AU666957B2 (en) 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5382591A (en) 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US5648074A (en) 1993-05-25 1997-07-15 Allergan Compositions and methods for disinfecting contact lenses and reducing proteinaceous deposit formation
WO1995005803A1 (en) * 1993-08-20 1995-03-02 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
JP3683908B2 (en) 1993-10-13 2005-08-17 アラーガン、インコーポレイテッド Method of using (2-imidazolin-2-ylamino) quinoxaline derivative
CA2134376C (en) * 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
US6294202B1 (en) * 1994-10-06 2001-09-25 Genzyme Corporation Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
US5558876A (en) 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
US5807541A (en) 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6472379B1 (en) * 1999-03-15 2002-10-29 Trustees Of Boston University Angiogenesis inhibition
ITMI991453A1 (en) 1999-07-01 2001-01-01 Farmila Farma Milano OPHTHALMIC COMPOSITIONS IN THE FORM OF AQUEOUS GEL
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
JP4132599B2 (en) * 2000-07-07 2008-08-13 日本板硝子株式会社 Image forming apparatus
EP1365811A2 (en) * 2000-07-14 2003-12-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198210A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US20040224010A1 (en) 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
TWI336257B (en) † 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
WO2005014046A2 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
WO2005101982A2 (en) 2004-03-24 2005-11-03 Sun Pharmaceutical Industries Limited A stable ophthalmic composition
AU2005322305B2 (en) 2004-12-23 2010-09-16 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US20070299124A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
AU2007208054A1 (en) 2006-01-25 2007-08-02 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
US20080039398A1 (en) 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20070287741A1 (en) 2006-06-13 2007-12-13 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals
CA2687717A1 (en) 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
KR20110008263A (en) 2008-04-24 2011-01-26 알러간, 인코포레이티드 Substituted gamma lactams as therapeutic agents
US20080275118A1 (en) 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2007091A (en) * 1977-11-07 1979-05-16 Toko Yakuhin Kogyo Kk Ophthalmic composition
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US6255299B1 (en) * 1985-01-07 2001-07-03 Leo Pharmaceutical Products Ltd. Opthalmic gel composition and method of treating eye infections
WO1992002515A1 (en) * 1990-07-31 1992-02-20 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US6056950A (en) * 1996-02-05 2000-05-02 Farmigea S.P.A. Ophthalmic solutions viscosified with tamarind seed polysaccharide
US20020103255A1 (en) * 1997-12-19 2002-08-01 Hellberg Mark R. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension

Also Published As

Publication number Publication date
AU2004263149A1 (en) 2005-02-17
ATE444732T1 (en) 2009-10-15
US20130296396A1 (en) 2013-11-07
PL1654002T5 (en) 2014-06-30
ES2332049T5 (en) 2014-03-27
US20150164863A1 (en) 2015-06-18
EP1654002B2 (en) 2014-01-29
EP1654002B1 (en) 2009-10-07
BRPI0413381A (en) 2006-10-17
US20050031697A1 (en) 2005-02-10
DK1654002T4 (en) 2014-02-17
DE602004023516D1 (en) 2009-11-19
DK1654002T3 (en) 2010-02-01
US8992952B2 (en) 2015-03-31
CA2534484A1 (en) 2005-02-17
AU2004263149B2 (en) 2010-08-19
EP1654002A2 (en) 2006-05-10
JP2007501799A (en) 2007-02-01
ES2593113T3 (en) 2016-12-05
US20210251961A1 (en) 2021-08-19
WO2005014046A2 (en) 2005-02-17
ES2332049T3 (en) 2010-01-25
EP2113246A1 (en) 2009-11-04
EP2113246B1 (en) 2016-06-22
PL1654002T3 (en) 2010-03-31
US8512717B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
WO2005014046A3 (en) Compositions for delivery of therapeutics into the eyes and methods for making and using the same
WO2004008990A3 (en) Multiple corneal inlays for gradual refractive correction
MXPA03008401A (en) Combination of brimonidine and timolol for topical ophthalmic use.
WO2004112836A8 (en) Ophthalmic compositions containing a synergistic combination of two polymers
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
MXPA03007590A (en) Compositions and methods for enhancing drug delivery across and into ocular tissues.
WO2002036162A3 (en) Compositions for treatment of ocular neovascularization and neural injury
WO2003074076A3 (en) Periocular drug delivery for diabetic retinopathy
WO2009111545A3 (en) Rotationally stabilized contact lenses and methods for their design
WO2006019893A3 (en) Intrastromal devices and method for improving vision
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
IL169287A (en) Sterile ophthalmic formulation, an ocular insert for delivery of same and the use of the formulation
WO2005011531A3 (en) Primary and supplemental intraocular lens system
WO2006007543A3 (en) Intracorneal lens insertion device
WO2003053358A3 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
WO2007146265A3 (en) Static progressive surface region in optical communication with a dynamic optic
WO2005020907A3 (en) Ocular drug delivery device
TW200501969A (en) Ophthalmic compositions containing a synergistic combination of three polymers
WO2003005941A3 (en) Insert for the treatment of dry eye
WO2007042040A3 (en) TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
WO2005101982A3 (en) A stable ophthalmic composition
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2009062750A3 (en) Active soluble post-translationally modified neuregulin isoforms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2534484

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004780382

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006522767

Country of ref document: JP

Ref document number: 2004263149

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004263149

Country of ref document: AU

Date of ref document: 20040805

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004263149

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004780382

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0413381

Country of ref document: BR